Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
SLAM DRILLS MORE COPPER MINERALIZATION AT GOODWIN (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc ONCY


Primary Symbol: T.ONC

Healthcare Biotechnology
Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Oncolytics Biotech Inc > Multiple thoughts.
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(5799)
•••
Comment by Noteableon Jun 14, 2024 10:11am
30 Views
Post# 36089011

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Multiple thoughts.

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Multiple thoughts." In an April 2005 episode, Stern asked Trump if there was ever a time when he had sex with Miss Universe or Miss USA contestants.

“I never comment on things like that,” Trump answered.

Later, Artie Lang interjects from the background, “Give us the first letter of the country you had sex with.”

“How many letters are there?” Trump joked.

Stern then posed a scenario wherein one of the beauty pageant contestants went up to Trump and asked to have sex with him.

“Now you’re not the type that would say no,” Stern said.

“I don’t want to hurt their feelings,” Trump replied."

Co-host Robin Quivers then asked Trump if sleeping with the contestants could be construed as a conflict of interest.

“It could be a conflict of interest,” Trump said. “But, you know, it’s the kind of thing you worry about later, you tend to think about the conflict a little bit later on.”

https://www.cnn.com/2016/10/08/politics/trump-on-howard-stern/
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities